4.8 Review

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

期刊

CIRCULATION
卷 137, 期 9, 页码 961-972

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.117.033502

关键词

cardiovascular and stroke endpoint definitions; cardiovascular and stroke outcome definitions; cardiovascular and stroke outcomes; cardiovascular endpoint definitions; cardiovascular endpoints; cardiovascular outcomes; clinical trial endpoint definitions; clinical trial endpoints; endpoint definitions; endpoints; outcome definitions; stroke endpoint definitions; stroke endpoints; stroke outcomes

资金

  1. Afferent
  2. Amgen
  3. Apple Inc.
  4. AstraZeneca
  5. Cardiva Medical Inc.
  6. Daiichi
  7. Ferring
  8. Google (Verily)
  9. Johnson Johnson
  10. Luitpold
  11. Medtronic
  12. Merck
  13. Novartis
  14. Sanofi
  15. St. Jude
  16. Tenax
  17. Janssen Pharmaceuticals
  18. Osprey Medical Inc.
  19. Eli Lilly/Daiichi-Sankyo
  20. Bristol-Myers Squibb
  21. Medicines Company
  22. OrbusNeich
  23. Bayer
  24. CSL Behring
  25. Abbott Laboratories
  26. Watermark Research Partners
  27. Novartis Pharmaceuticals
  28. AUM Cardiovascular, Inc.
  29. Beth Israel Deaconess Medical Center
  30. Abbvie
  31. Cerenis
  32. Eli Lilly
  33. Esperion
  34. Pfizer
  35. Orexigen
  36. Arena
  37. Eisai
  38. Aegerion
  39. Angelmed
  40. Janssen
  41. Xoma
  42. ICON Clinical
  43. Boston Clinical Research Institute
  44. Boehringer Ingelheim
  45. Alnylam
  46. Bellerophon
  47. Celladon
  48. Gilead
  49. GlaxoSmithKline
  50. Ionis Pharmaceutics
  51. Lone Star Heart
  52. Mesoblast
  53. Myo-Kardia
  54. National Institutes of Health/National Heart, Lung, and Blood Institute
  55. Sanofi Pasteur
  56. Theracos
  57. Celyad
  58. Cytokinetics
  59. Trevena
  60. Abbott
  61. Daiichi-Sankyo
  62. GlaxoSmith-Kline
  63. Roche Diagnostics
  64. Takeda
  65. American Orthotics
  66. Prosthetics Association
  67. Philips/Volcano
  68. Micell
  69. Venarum
  70. Boston Scientific
  71. CeloNova
  72. Abbott/St. Jude Medical
  73. Relypsa
  74. Cheetah Medical
  75. Medical Research Council
  76. British Heart Foundation
  77. Cancer Research UK
  78. National Institute for Health Research
  79. CSL
  80. Abiomed
  81. AUM Cardiovascular
  82. Ablative Solutions
  83. Biotronik
  84. Corvia

向作者/读者索取更多资源

This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the US Food and Drug Administration (FDA). The FDA established the Standardized Data Collection for Cardiovascular Trials Initiative in 2009 to simplify the design and conduct of clinical trials intended to support marketing applications. The writing committee recognizes that these definitions may be used in other types of clinical trials and clinical care processes where appropriate. Use of these definitions at the FDA has enhanced the ability to aggregate data within and across medical product development programs, conduct meta-analyses to evaluate cardiovascular safety, integrate data from multiple trials, and compare effectiveness of drugs and devices. Further study is needed to determine whether prospective data collection using these common definitions improves the design, conduct, and interpretability of the results of clinical trials.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cardiac & Cardiovascular Systems

High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis

Mark C. Petrie, Pardeep S. Jhund, Eugene Connolly, Patrick B. Mark, Michael R. MacDonald, Michele Robertson, Stefan D. Anker, Sunil Bhandari, Kenneth Farrington, Philip A. Kalra, David C. Wheeler, Charles R. Tomson, Ian Ford, John J. McMurray, Iain C. Macdougall

Summary: This study aimed to investigate the effect of high-dose vs. low-dose intravenous iron on myocardial infarction in patients on maintenance haemodialysis. The results showed that high-dose IV iron reduced myocardial infraction in patients receiving haemodialysis.

CARDIOVASCULAR RESEARCH (2023)

Article Cardiac & Cardiovascular Systems

Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial

Kieran F. Docherty, John J. V. McMurray, Brian L. Claggett, Zi Michael Miao, Kirkwood F. Adams, Alexandra Arias-Mendoza, John G. F. Cleland, Rafael Diaz, Luis E. Echeverria Correa, G. Michael Felker, Candida Fonseca, Jing Li, Marco Metra, Karen Sliwa-Hahnle, Scott D. Solomon, Hans J. Vandekerckhove, Dragos Vinereanu, Adriaan A. Voors, Stephen B. Heitner, Stuart Kupfer, Fady I. Malik, Lisa Meng, John R. Teerlink

Summary: This study aimed to examine the effect of omecamtiv mecarbil in heart failure patients according to the NT-proBNP levels. The results showed that omecamtiv mecarbil had a greater benefit in patients with higher baseline NT-proBNP levels, especially those without atrial fibrillation/flutter.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Article Cardiac & Cardiovascular Systems

Cost-effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure

Robert J. H. Miller, Derek S. Chew, Lei Qin, Nowell M. Fine, Jieling Chen, John J. V. McMurray, Jonathan G. Howlett, Phil McEwan

Summary: This study compares the cost-effectiveness of immediate and 12-month delayed initiation of dapagliflozin treatment in patients with a history of hospitalization for heart failure from different healthcare perspectives. Using a decision-analytic Markov model, the study found that immediate initiation of dapagliflozin reduces heart failure events and cardiovascular mortality. Immediate initiation of dapagliflozin provides greater clinical benefits and should be considered standard of care.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Review Cardiac & Cardiovascular Systems

Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis

James P. Curtain, Matthew M. Y. Lee, John J. McMurray, Roy S. Gardner, Mark C. Petrie, Pardeep S. Jhund

Summary: In this meta-analysis, we examined the efficacy of implantable haemodynamic monitoring (IHM)-guided care in patients with heart failure (HF). The results showed that IHM-guided care reduced HF hospitalisations and worsening HF events across all ejection fraction (EF) ranges. However, the effect of IHM-guided care on worsening HF events in patients with HFpEF (EF >= 50%) was uncertain and further studies are needed.
Article Cardiac & Cardiovascular Systems

Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction

Leanne Mooney, Colette E. Jackson, Carly Adamson, Alex McConnachie, Paul Welsh, Rachel C. Myles, John J. V. McMurray, Pardeep S. Jhund, Mark C. Petrie, Ninian N. Lang

Summary: Circulating levels of interleukin-6 may identify patients at greater risk of adverse outcomes following hospitalization with heart failure with preserved ejection fraction.

CIRCULATION-HEART FAILURE (2023)

Article Cardiac & Cardiovascular Systems

Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial

Karola S. Jering, Brian L. Claggett, Marc A. Pfeffer, Christopher B. Granger, Lars Kober, Eldrin F. Lewis, Aldo P. Maggioni, Douglas L. Mann, John J. V. McMurray, Margaret F. Prescott, Jean L. Rouleau, Scott D. Solomon, Phillippe Gabriel Steg, Dirk von Lewinski, Eugene Braunwald

Summary: NT-proBNP is an important prognostic factor in patients with acute myocardial infarction and certain risk factors. It is associated with heart failure, death, and atherosclerotic events, and this predictive information is independent of hs-cTnT.

CIRCULATION-HEART FAILURE (2023)

Review Cardiac & Cardiovascular Systems

Optimizing outcomes in heart failure: 2022 and beyond

Ewa A. Jankowska, Tomas Andersson, Claudia Kaiser-Albers, Biykem Bozkurt, Ovidiu Chioncel, Andrew J. S. Coats, Loreena Hill, Friedrich Koehler, Lars H. Lund, Theresa McDonagh, Marco Metra, Clemens Mittmann, Wilfried Mullens, Uwe Siebert, Scott D. Solomon, Maurizio Volterrani, John J. V. McMurray

Summary: Despite the rapid development of therapies and tools for heart failure (HF), everyday management in clinical practice remains suboptimal. A workshop convened by the European Society of Cardiology (ESC) identified barriers, such as the complexity of HF and its treatment, financial constraints, failure to meet patient needs, suboptimal outpatient management, and fragmented healthcare systems. Ongoing initiatives and proposed actions aim to address these barriers and improve patient outcomes.

ESC HEART FAILURE (2023)

Article Cardiac & Cardiovascular Systems

Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure

Toru Kondo, Xiaowen Wang, Mingming Yang, Pardeep S. Jhund, Brian L. Claggett, Muthiah Vaduganathan, Adrian F. Hernandez, Carolyn S. P. Lam, Silvio E. Inzucchi, Felipe A. Martinez, Rudolf A. de Boer, Mikhail N. Kosiborod, Akshay S. Desai, Lars Kober, Piotr Ponikowski, Marc S. Sabatine, Anna Maria Langkilde, Magnus Petersson, Natalia Zaozerska, Erasmus Bachus, Scott D. Solomon, John J. V. Mcmurray

Summary: The efficacy and safety of dapagliflozin were consistent across global regions despite geographic differences in patient characteristics, background treatment, and event rates.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction

Shingo Matsumoto, Toru Kondo, Pardeep S. Jhund, Ross T. Campbell, Karl Swedberg, Dirk J. van Veldhuisen, Stuart J. Pocock, Bertram Pitt, Faiez Zannad, John J. V. McMurray

Summary: This study evaluated the safety and efficacy of eplerenone according to the duration of heart failure with reduced ejection fraction (HFrEF). The results showed that the benefits of eplerenone were consistent regardless of HFrEF duration, with the longest-duration group experiencing the greatest absolute benefit.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Article Urology & Nephrology

Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

Robert A. Fletcher, Niels Jongs, Glenn M. Chertow, John J. V. Mcmurray, Clare Arnott, Meg J. Jardine, Kenneth W. Mahaffey, Vlado Perkovic, Patrick Rockenschaub, Peter Rossing, Ricardo Correa-Rotter, Robert D. Toto, Muthiah Vaduganathan, David C. Wheeler, Hiddo J. L. Heerspink, Brendon L. Neuen

Summary: This study analyzed the effect of SGLT2 inhibitors on the discontinuation of RAS blockade and found that patients receiving SGLT2 inhibitors had a lower risk of discontinuing RAS blockade. This effect was particularly pronounced in patients with a high baseline urinary albumin-to-creatinine ratio.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Review Cardiac & Cardiovascular Systems

Effects of renin-angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials

Matthew M. Y. Lee, Toru Kondo, Ross T. Campbell, Mark C. Petrie, Naveed Sattar, Scott D. Solomon, Muthiah Vaduganathan, Pardeep S. Jhund, John J. Mcmurray

Summary: This meta-analysis evaluates the safety and efficacy of renin-angiotensin system (RAS) blockers in the treatment of COVID-19. The results suggest that ACE inhibitors and ARBs can be continued in non-severe patients, but initiation of RAS blockers may be harmful in critically ill patients.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2023)

Article Cardiac & Cardiovascular Systems

A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies

Joanna Osmanska, Katriona Brooksbank, Kieran F. Docherty, Stacy Robertson, Kirsty Wetherall, Alex McConnachie, Jerry Hu, Roy S. Gardner, Andrew L. Clark, Iain B. Squire, Paul R. Kalra, Pardeep S. Jhund, Pieter Muntendam, John J. McMurray, Mark C. Petrie, Ross T. Campbell

Summary: This study compared the bioavailability, pharmacokinetic and pharmacodynamic profiles between subcutaneous and intravenous furosemide, and described the use of a mini-pump for subcutaneous administration. The results showed that subcutaneous furosemide had similar bioavailability to intravenous furosemide, and administration via a patch pump was feasible and well tolerated.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2023)

Meeting Abstract Cardiac & Cardiovascular Systems

Duration of heart failure with preserved ejection fraction and treatment with sacubitril/valsartan: insights from the PARAGON-HF trial

John Ostrominski, B. Claggett, M. Packer, M. Pfeffer, C. Lam, M. Zile, A. Desai, P. Jhund, M. Lefkowitz, J. Mcmurray, S. Solomon, M. Vaduganathan

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Meeting Abstract Endocrinology & Metabolism

Effects of dapagliflozin in type 2 diabetes and heart failure with mildly reduced or preserved ejection fraction across the background of glucose-lowering therapy in DELIVER

M. Vaduganathan, S. E. Inzucchi, B. L. Claggett, I. Kulac, R. A. de Boer, A. S. Desai, K. F. Docherty, A. F. Hernandez, M. N. Kosiborod, P. S. Jhund, C. S. P. Lam, F. A. Martinez, S. J. Shah, J. J. V. McMurray, S. D. Solomon

DIABETOLOGIA (2023)

暂无数据